Dec. 16 at 8:10 PM
$BMBL Mainz Biomed when I see Quest in the mix I immediately think about scale readiness, because scaling a screening test is not only about a good biomarker, it is about logistics, processing, consistency, and throughput, Quest is a name associated with doing that at scale, now put that next to 150 sites and 15,000 subjects and it feels like a serious build, price 1.03, float 8.51M, cap 8.85M, PT 14 +1,328.57% 🚀